| (AIM: SAR) | 26 November 2014 |
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Issue of Options
The Company announces that it has granted the following share options (the "Options") to Tim Mitchell, Chief Executive Officer, John Reader, Chief Scientific Officer and Paul Harper, Non-Executive Chairman;
| Number of options | |
| Tim Mitchell | 7,198,353 |
| John Reader | 7,198,353 |
| Paul Harper | 1,227,059 |
The Options have been granted with an exercise price of 0.425 pence and are exercisable until 25 November 2024. The Options will vest subject to pre-determined performance criteria.
In addition to the Options being granted, Tim Mitchell and John Reader currently each hold the following options:
| Exercise period | Number of options | Exercise price |
| 4 December 2009 - 4 December 2019 | 6,400,000 | 0.25 pence |
| 22 December 2010 - 22 December 2020 | 6,153,846 | 0.26 pence |
| 13 March 2012 - 13 March 2022 | 2,566,666 | 1.2 pence |
| 18 December 2013 - 18 December 2023 | 4,752,000 | 0.6 pence |
In addition to the Options being granted, Paul Harper holds the following options:
| Exercise period | Number of options | Exercise price |
| 18 December 2013 - 18 December 2023 | 810,000 | 0.6 pence |
Enquires:
| Sareum Holdings plc | |
| Tim Mitchell, Chief Executive Officer | 01223 497 700 |
| Sanlam Securities UK Limited (Nominated Adviser) | |
| Simon Clements / James Thomas | 020 7628 2200 |
| Hybridan LLP (Broker) | |
| Claire Noyce / William Lynne | 0203 713 4581/ 4582 |
| The Communications Portfolio (Media enquiries) | |
| Ariane Comstive [email protected] | 020 7536 2028 / 2029 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.
For further information, please visit www.sareum.co.uk
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SAREUM HOLDINGS PLC via Globenewswire